The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Ippolito Vincent P since 2010.
The trader's CIK number is 1430426.
At the time of the last reporting, Ippolito Vincent P was the EVP, Sales & Marketing of Anacor Pharmaceuticals Inc. (stock ticker symbol ANAC).
Also see all insider trading activities at Anacor Pharmaceuticals Inc.
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2016 | ANAC | 0 | $0 | 29,855 | $2,580,088 | 20,000 | $399,200 |
2015 | ANAC | 0 | $0 | 29,000 | $2,557,451 | 20,000 | $399,200 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2011 | MRX | 0 | $0 | 114,356 | $4,216,877 | 100,000 | $2,890,300 |
2010 | MRX | 0 | $0 | 13,012 | $349,970 | 0 | $0 |
1. Anacor Pharmaceuticals Inc (ANAC)
2. Medicis Pharmaceutical Corp (MRX)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2016-03-02 | ANAC | Sale | 9,000 | 63.72 | 573,489 |
2016-01-19 | ANAC | Option Ex | 20,000 | 19.96 | 399,200 |
2016-01-19 | ANAC | Sale | 20,000 | 95.54 | 1,910,780 |
2016-01-04 | ANAC | Sale | 855 | 112.07 | 95,819 |
2015-12-09 | ANAC | Sale | 20,000 | 108.04 | 2,160,740 |
2015-12-09 | ANAC | Option Ex | 20,000 | 19.96 | 399,200 |
2015-03-03 | ANAC | Sale | 9,000 | 44.08 | 396,711 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2011-05-13 | MRX | Option Ex | 100,000 | 28.90 | 2,890,300 |
2011-05-13 | MRX | Sale | 114,356 | 36.88 | 4,216,877 |
2010-08-12 | MRX | Sale | 13,012 | 26.90 | 349,970 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Ippolito Vincent P (EVP, Sales & Marketing of Anacor Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.